The DIRECT molecular monitoring platform - identifying patients suitable for novel agent clinical trials (STAGE1).
The aim of the DIRECT Study is to establish a robust pipeline to identify those patients with high-grade B cell lymphoma most suitable for novel agent clinical trials based upon genomic subtype and an integrated response evaluation determined early in first-line therapy.
This will be done by integrating data and samples collected from patients undergoing standard of care treatment for high-grade B cell lymphoma.
The trial is being funded jointly by AstraZeneca and the Cancer Research UK Cambridge Centre as well as being a flagship trial for MFICM. It opened to recruitment in September and currently has 37 patients recruited across 4 sites, with another site about to open.
Data will be integrated from
The Mark Foundation Institute for Integrated Cancer Medicine (MFICM) at the University of Cambridge aims to revolutionise cancer care by affecting patients along their treatment pathway.